Financial Performance - As of March 31, 2025, the company reported a net income of $454,300, primarily from interest income on marketable securities held in the trust account [125]. - The company has incurred a net loss of $2,091 from inception through March 31, 2024, related to formation and operating expenses [125]. IPO and Fundraising - The company completed its IPO on September 13, 2024, issuing 5,000,000 Units at $10.00 per Unit, generating gross proceeds of $50,000,000, with offering costs of $1,845,513 [120]. - An over-allotment option was exercised, generating an additional $7,500,000 in gross proceeds, bringing total funds raised to $57,500,000 [120]. - The company intends to use net proceeds from the IPO to acquire target businesses and cover related expenses [127]. - All 5,750,000 Ordinary Shares sold in the IPO contain a redemption feature, allowing for redemption in connection with liquidation or business combination [138]. Financial Position - The company had cash of $1,142,445 and marketable securities of $59,218,058 in the Trust Account as of March 31, 2025 [126]. - The company has no long-term debt or off-balance sheet arrangements as of March 31, 2025 [131]. - The company is obligated to pay a deferred underwriting commission of $575,000 to underwriters from the Trust Account [132]. Going Concern - The company expects to incur significant costs related to being a public company and pursuing a business combination, raising concerns about its ability to continue as a going concern [130]. Accounting Standards - FASB issued ASU 2023-07 requiring annual and interim disclosures of significant segment expenses and other segment items for public entities, effective for fiscal years beginning after December 15, 2023 [142]. - ASU 2023-09 mandates expanded disclosures of income taxes paid and incremental income tax information, effective for fiscal years beginning after December 15, 2024 [143]. - Company management believes that the adoption of ASU 2023-09 will not have a material impact on financial statements and disclosures [143]. - Company does not anticipate any material effect from recently issued accounting standards that are not yet effective [144]. - As a smaller reporting company, there are no required disclosures under market risk [145].

FORM 8-K CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2025 Dermata Therapeutics, Inc. (Exact name of registrant as specified in its charter) (State or Other Jurisdiction of Incorporation) (Commission File Number) Delaware 001-40739 86-3218736 (I.R.S. Employer Identification No.) (Address of principal executive offices) (Zip Code) (858) 800 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from ___________ to ___________ Commission File Number: 001-40739 DERMATA THERAPEUTICS, INC. (Exact name of registrant as specified in the charter) | Delaware | 86-3218736 | | - ...

"Excluding a single, multi-million-dollar deal recorded in the year-ago fiscal second quarter, our business generated double-digit sales growth in the fiscal second quarter compared to the year- ago period," commented Victor Dellovo, Chief Executive Officer. "The prior year multi-million- dollar sale has proven to be successful resulting in the customer renewing customer support for twelve months in a six-figure contract during the fiscal second quarter. Despite challenging operating conditions, we're pleas ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 Commission File Number: 001-42037 (Exact Name of Registrant as Specified in its Charter) | Delaware | 27-2345075 | | --- | --- | | ( State or other jurisdiction of | (I.R.S. Employer | | incorporation or organization) | Identification No.) | | 1440 N Union Bower Rd, Irving, TX | 75061 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________________ to __________________ IO Biotech, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 87-0909276 (State or other jurisdictio ...

For immediate release May 14, 2025 Star Equity Holdings, Inc. Announces 2025 First Quarter Financial Results Q1 2025 revenues increased to $12.9 million vs. $9.1 million in Q1 2024 Alliance Drilling Tools acquisition marks entry into Energy Services Quarter-end Building Solutions backlog stands at record $27.9 million Old Greenwich, CT. - Star Equity Holdings, Inc. (Nasdaq: STRR; STRRP) ("Star" or the "Company"), a diversified holding company, reported today its financial results for the first quarter (Q1) ...

For immediate release May 14, 2025 Star Equity Holdings, Inc. Announces 2025 First Quarter Financial Results Q1 2025 revenues increased to $12.9 million vs. $9.1 million in Q1 2024 Alliance Drilling Tools acquisition marks entry into Energy Services Quarter-end Building Solutions backlog stands at record $27.9 million Old Greenwich, CT. - Star Equity Holdings, Inc. (Nasdaq: STRR; STRRP) ("Star" or the "Company"), a diversified holding company, reported today its financial results for the first quarter (Q1) ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR Securities registered pursuant to Section 12(b) of the Act: | | Trading | | | --- | --- | --- | | Title of each class | Symbol(s) | Name of each exchange on which registered | | Common stock, par value $0.001 per share | ULY | NASDAQ | Indicate by check mark whether the registrant ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K ________________________ CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2025 ________________________ 945 Concord Street Framingham, Massachusetts 01701 (Address of principal executive offices) (Zip Code) (781) 778-7720 (Registrant's telephone number, including area code) Xenetic Biosciences, Inc. (Exact name of registrant as specif ...